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Macrophage colony-stimulating factor (M-CSF)' is one of several cytokines that
control the differentiation of monocytes and macrophages. In human and murine
bone marrow cultures it stimulates the proliferation and differentiation of macro-
phage progenitors (1, 2), and it has been shown to exert a similar effect on murine
pulmonary macrophages in vitro (3). Murine peritoneal macrophages exposed to
M-CSF exhibit increased cytotoxicity against certain tumor cell targets, especially
in the presence ofother T cell-derived factors (4-6), and undergo morphologic and
biochemical alterations indicative of cellular activation (7-9).
Macrophages possess the ability to kill certain tumor cells in vitro, and cytotox-
icity is enhanced by activation with endotoxin, IFN-y or other cytokines (reviewed
in reference 10). It has been more difficult to demonstrate significant antitumor cy-
totoxicity in fresh unstimulation monocytes, but granulocyte/macrophage CSF(GM-
CSF) (11) and M-CSF (12)have been reportedto induce tumor cell killing in mono-
cytes afterabriefculture period. Whencultured with human serum (13-15)orcytokines
(16, 17), monocytes undergo in vitrodifferentiation intolarge, macrophage-like cells.
Both macrophages and monocytes are capable ofmediating antibody-dependent cel-
lular cytotoxicity (ADCC) usingmurine mAbs against human tumor cells (18-23).
One possible mechanism ofmacrophage ADCC is phagocytosis (24, 25). Since most
conventional cytotoxicity assays rely on the release ofan intracellular radioisotope
after target cell death or injury, it is possiblethat phagocytosis, by masking this iso-
tope release, may cause such assays to underestimate cytotoxicity. In this study we
investigated the abilityofhumanmonocytes cultured in M-CSFto mediate antitumor
ADCC using a novel colorimetric assay unaffected by the mechanismofcell killing.
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ANTITUMOR ADCC BY CULTURED MONOCYTES
Antiganglioside mAbs were used against human neuroblastoma andmelanoma cell
lines .
Materials and Methods
Cell Lines.
￿
SKMel-1 and SKMel-28 were obtained from the American Type Culture Col-
lection (ATCC ; Rockville, MD) . SKMel-31 was provided byDr. Alan Houghton, Memorial
Sloan-Kettering Cancer Center. LAN-1 was obtained from Dr . Robert Seeger, and M-14 from
Dr. Reiko Irie, both ofUCLA, Los Angeles, CA . LAl-15n was provided byDr. June Biedler,
Memorial Sloan-Kettering . Cell lines were propagated in RPMI 1640 (Gibco Laboratories,
Grand Island, NY) supplemented with 10% bovine serum (HyClone Laboratories, Logan,
UT), 100 U/ml penicillin G, and 100 lAg/ml streptomycin (BS-RPMI) . Cell lines used for
in vitro assays were >90% viable by trypan blue exclusion .
Monoclonal Antibodies .
￿
The murine mAb 3178 (IgG3, anti-GD2), developed in our labora-
tory, has been previously described (26) . F(aU)2 fragments were prepared from purified 3178
as described (27) . R24 (IgG3, anti-GD3) was the generous gift ofDr. Alan Houghton, and
the antibody 10-11 (anti -GM2) was the gift of Dr. Philip Livingston, Memorial Sloan-
Kettering . HSAN1.2 was the gift ofDr. Patrick Reynolds, UCLA . Other antineuroblastoma
antibodies derived in our laboratory include 3A5 (IgG2n), 5177 (IgG3), both against a
glycolipid antigen other than GDS and 51711 (IgM anti-GD2). 3G8 (anti-CD16) was generously
provided by Dr. Jay Unkeless, Mt . Sinai Medical School, New York, NY. Leu19 and FITC-
conjugated Leull (anti-CD16) were purchased from Becton Dickinson & Co ., (Mountain
View, CA) . Antimonocyte antibody MY4 (anti-CD14) was generously provided byDr. James
Griffin, Harvard Medical School, Boston,MA . Anti-la (clone L243) was obtained fromATCC .
Cytokines.
￿
Recombinant human M-CSF (8 x 10 5 U/mg) was generously supplied by
Genetics Institute, Cambridge, MA . Endotoxin (purified Escherichia coli LPS) was obtained
from Sigma Chemical Co . (St . Louis, MO) .
Separation and Culture ofPeripheral BloodMonocytes.
￿
Blood was obtained from healthy volun-
teer donors, anticoagulated with 20 U/ml heparin, and centrifuged on Ficoll-Paque (Phar-
macia Fine Chemicals, Piscataway, NJ) for 20 min at 200 g. The mononuclear cell fraction
was washed twice, and spun over a cushion of36% Percoll (Pharmacia Fine Chemicals) in
HBSS at 400 g for 5 min to remove platelets . The cells were enriched for monocytes using
a modification of the method ofGmelig-Meyling and Waldmann (28), by centrifugation over
a single-step gradient of 47% percoll at 1,000 g for 20 min . The interface layer contained
>95% of the starting monocyte population, and was typically 40% monocytes by size and
granularity on flow cytometry . These cells were suspended in BS-RPMI and allowed to ad-
here for 1-2 h in 96-well flat-bottomed tissue culture plates (Falcon Labware, Oxnard, CA)
at a concentration of 1.6 x 105 cells per well . The plates were washed vigorously in RPMI
plus 0.1% human serum albumin using a multichannel pipette . Typically, 3-4 x 104 cells
(about half ofthe starting monocyte population) remained adherent after washing, as deter-
mined by flow cytometry on the nonadherent cells and enumeration ofadherent cells detached
with EDTA . The adherent cells were >95% monocytes by morphology using Wright's stain .
Cell counts after activation were typically 3-5 x 10 4 cells per well, and all cells were mono-
cyte/macrophages by morphology.
Adherent cells were cultured for 9-12 d in 150 ul ofmedium : either 10% BS-RPMI sup-
plemented with growth factors, or20% human serum in RPMI . Human serum was obtained
from volunteerdonors, allowed to clot at 37°C for 30 min, centrifuged, and frozen at -70°C
until used . Medium containinghuman serum was changed every 3-4 d . All media and factors
used in the culture of monocytes were screened for endotoxin using a limulus amebocyte
lysate assay (Associates of Cape Cod, Woods Hole, MA) and contained <0.03 EU/ml in the
concentrations used .
ELISA for Cytotoxicity.
￿
Target cells were added directly to the 96-well plates containing
cultured monocytes at 0.5, 1, 2, or 4 x 104 targets per well in 100 J,1 ofBS-RPMI (giving
nominal E/T ratios of 8, 4, 2, and 1 respectively) . Antibody (or medium) was added in 25
ul ofBS-RPMI . For 24-h assays, antibody was added at the beginning of the assay. For 72-hMUNN AND CHEUNG
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assays, the target cells were allowed to adhere overnight before the addition of antibody, since
Gm and GD3 may play a role in the attachment of some cell lines (29). Control wells receiving
antibody but no monocytes typically had 5-20% fewer cells at the end of 72 h, when com-
pared with targets incubated in medium alone. To adjust for any antiproliferative effects of
antibody, all cytotoxicity data were calculated based on parallel controls containing target
cells cultured under identical conditions of antibody, medium, and cytokines. After incuba-
tion, the plates were centrifuged at 400g for 5 min to recover any detached cells, the superna-
tant was aspirated, and the plates were air-dried and fixed with glutaraldehyde (1% vol/vol
in PBS) for 5 min. After thorough washing with PBS using an automated plate washer (Dy-
natech Laboratories, Alexandria, VA), the plates were incubated with 10% BS in PBS for
1 h at 37°C to block nonspecific binding of antibody, then washed and incubated with an
mAb specific for the target cell's. For SKMel-1 and SKMel-28, the primary antibody was
R24 (IgG3, anti-GD3) at a 1 :500 dilution of ascites; for the other targets, 3F8 (IgG3, anti-
GD2) was used at 2,ug/ml in BS-PBS. After washing, peroxidase-conjugated goat anti-mouse
IgG3 (Fisher-Biotech, Pittsburgh, PA) was added in BS-PBS, and bound peroxidase was mea-
sured as previously described (26). Optical density (OD) was read as absorbance at 490 nm
using a Dynatech automated plate reader (UV 700) connected to an IBM-AT computer. For
every data point, two parallel controls were performed: OD oftumor targets cultured without
effector cells, and OD of effector cells cultured without targets (typically <5% of the signal
from targets alone). The percentage of surviving target cells was calculated using the for-
mula: Percent surviving = 100 x {[OD (targets + effectors) - OD (effectors alone)]/[OD
(targets alone)J}. This was converted to percent cytotoxicity using the formula: percent cyto-
toxicity = 100% - percent surviving targets. Determinations were performed in duplicate
and the mean was reported.
Radionuclide Release Assays.
￿
Target cells were labeled with either "Cr (100'Ci/106 cells)
in 500,ul medium for 1 h, or [3H]TdR (50 pCi/106 cells) in 10 ml medium for 18 h. Labeled
target cells were washed and added to M-CSFcultured monocytes as described above, and
incubated for 24 h at 37 °C. The plates were centrifuged and 100 Al of supernatant was re-
moved for counting in either a gamma counter ("Cr) or liquid scintillation counter (3H).
Total release was determined by lysing labeled tumor cells with 0.1% Triton (Sigma Chemical
Co.); background release was measured using target cells without effectors. Cytotoxicity was
calculated using the formula: Percent cytotoxicity = 100 x {[cpm (targets + effectors) -
cpm (targets alone)]/[cpm (triton treated targets) - cpm . (targets alone)]}.
Proliferation Assays.
￿
Target cells, antibody, and M-CSFcultured monocytes were co-incu-
bated for 72 h as described above, then detached with 2 mM EDTA (30 min, at 37°C) diluted
1 :64 in fresh medium, and allowed to proliferate for 8-10 d (until the control wells had reached
confluent tumor growth). As controls, targets were incubated with 3F8 alone or with effectors
alone, then treated as above. Plates were screened for proliferating target cells using the MTT
formazan reduction assay described by Mosmann (30). The wells were also examined for
individual tumor colonies, which were readily visible using a phase-contrast inverted mi-
croscope.
Immunofluorescence and Flow Cytometry.
￿
M-CSFcultured monocytes were co-incubated with
target cells and 3F8 antibody as described, then detached with 2 mM EDTA. With vigorous
pipetting all the cells detached and were >90% viable by trypan blue exclusion. The cell sus-
pension was stained with a mixture of five mAbs to neuroblastoma (5F7, 5F11, 10-11, 3A5,
and HSAN1.2). Five controls were cultured and stained in identical fashion: macrophages
alone (incubated with and without antibody), target cells alone (with and without antibody),
and targets plus macrophages without antibody. After washing, the cells were incubated with
biotinylated goat anti-mouse IgG (ICN Immunobiologicals, Lisle, IL), followed by avidin-
phycoerythrin (Becton Dickinson & Co.). Monocytes were counterstained with Leull-FITC.
(The target cell lines used were unreactive with Leull-FITC.) Stained cells were analyzed
using a Becton Dickinson & Co. FACScan flow cytometer.
Cultured monocytes were also stained with mAbs Leu19, OKMI, L243, 3G8, and MY4,
followed by FITC-conjugated goat anti-mouse IgG. Irrelevant antibodies (IgG,) were used
as negative controls.514
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Results
Radionuclide-release Assays Underestimate Cytotoxicity by Cultured Monocytes.
￿
Neuro-
blastoma and melanoma target cells growing in tissue culture can be distinguished
from cultured monocytes on the basis of morphology. In preliminary experiments,
visual inspection with phasecontrast microscopy had suggestedthat target cell eradi-
cation was nearly complete after co-incubation with cultured monocytes and an-
titumor antibody (3F8). However, this degree of cytotoxicity was not evident when
two conventional radionuclide-release assays ([3H]TdR and "Cr) were used to de-
tect target cell lysis. Fig. 1 shows parallel 18-h ADCC assays using both methods
on twodifferenttarget cell lines. Theeffector cells were the same in all assays (mono-
cytes cultured for 10 d in 100 U/ml M-CSF), as was the antibody (3F8). The chro-
mium release assay did not show significant killingof either target cell line, and the
thymidine release assay gave inconsistent results depending on the target cell line
used. However, when we assayed for surviving tumor cells using a novel ELISA
method, we found a level of cytotoxicity that correlated well with visual inspection,
but that wasmuch higher than predictedby either isotope release method (alsoshown
in Fig. 1).
The technique used to detect survivingtarget cells was a variation of the conven-
tional ELISA, with survivingtumorcells(glutaraldehyde fixed) used as theadsorbed
antigen, and tumor-specific anti-GD2 or anti-GD3 mAbs used as the primary anti-
body (see Materials and Methods). Due to the fact that cultured monocytes showed
high nonspecific binding of most antibody subclasses, we found that only IgG3 an-
tibodies worked satisfactorily in ourassay. Ourmost frequently used target (SKMel-1)
expressed both GD2 and GD3 on >96% of cells, so the ADCC (co-incubation) assay
could be performed using 3F8 (anti-GD2) antibody, and the ELISA using an un-
related anti-GD3 antibody (R24). Flow cytometry on SKMel-1 and other melanoma
and neuroblastoma cell lines had previously shown identical patterns of reactivity
with both antibodies after 72 h of culture alone or with either antibody, indicating
that these antigens did not modulate or comodulate in the presence of antibody.
Our other target cell lines expressed primarily either GD2 or GD3 alone, so the same
antibody was used for both ADCC and ELISA. Since no modulation of these an-
tigens was observable by flow cytometry, andno population of antigen-negative cells
emerged after exposure to antibody, we considered this approach acceptable. (Fur-
ther proof that our ELISA method actually reflected target cell death rather than
antigen modulation was provided by the flow cytometry and tumor outgrowth ex-
periments described below.)
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FIGURE 1.
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Underestimation ofADCC by
radionuclide release assays. Human pe-
ripheral bloodmonocyteswere cultured for
11 d in minimal medium with 100 U/ml
M-CSF, then used as effector cells in one
of three parallel ADCC assays: ELISA
(open circles), thymidinerelease(solidcircles),
or chromium release (open squares). All
assays contained 3F8 antibody (2 ug/ml)
andwere incubatedfor18 h. Cytotoxicity
was calculated as described in Materials
and Methods. (A) SKMel-31 target cells;
(B) SKMel-1 target cells.The ELISA typically showed a 5-20%variationin cellnumberbetween antibody-
treated and untreated cells in the absence of effector cells; this was attributable to
amild growth-inhibitory effect ofantibody (especially3178)on some target cell lines.
To control for this variation we always calculated cytotoxicity relative to target cells
incubated under identical conditions ofantibody, medium, and M-CSFconcentra-
tion. There was close agreement between measurements of target cell number by
ELISA and by MTT reduction (r = 0.997), even after 72 h incubation with anti-
body. The ELISA could reliably detect 2-4 x 102 tumor cells per well, while con-
trol wells typically contained 2-8 x 10 4 tumor cells after 72 h. Thus, 1% surviving
target cells (99% cytotoxicity) could be detected by our ELISA method.
To prove that cultures without detectable antigen were truly free oftumor cells,
we performed the experiment shown in Fig. 2. Neuroblastoma cells and cultured
monocytes were co-incubated for 72 h, harvested with EDTA, and stained with a
mixture of5antibodies againstneuroblastoma (see Materials and Methods). Mono-
cytes were identified with Leull (anti-CD16). After co-incubation without antibody
(E/T ratio 4:1), 19% ofthe combined cell population bore tumor surface antigens;
when 3178 was present during the incubation <2% ofcells bore tumor markers (the
limits ofdetection for this assay). Identical results were obtained when 3178 alone
was used to identify tumor cells, instead of the antibody cocktail.
For tumor outgrowth experiments, we performed an ADCC assay as described
above, thenharvestedthe cells with EDTA, diluted them 1:64 in freshmedium, and
allowed residual target cells to proliferate for 8-10 d. By this point the two controls
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Two-color immunofluorescent staining and flow cytometry demonstrate the absence
oftumor cells after ADCC by M-CSFcultured monocytes. Human peripheral blood monocytes
were cultured for 10 d in minimal medium with 100 U/ml M-CSF Neuroblastoma target cells
(LAl-15n, E/T - 4:1) were added and co-incubated for 72 h, either without (A) or with (B) 2
jtg/ml of3178 antibody. As controls, target andeffectorcells were cultured separately under iden-
tical conditions. All cells were harvested with EDTA and stained with a mixtureoffive antitumor
antibodies indirectly linked to PE. Macrophages were counterstained with Leull (anti-CDI6)-
FITC. The regions as drawn contained 98% of the tumor cell controls in region 1 (whether cul-
tured with or without 3F8), and 98% ofmacrophage controls in region 2. (A) After co-cultivation
without 3178, 19% ofthe cells harvested fell within region 1. When 3178 was present during the
co-incubation <2% of cells fell in region 1 (B). The figure shows one of three similar experi-
ments using two different cell lines.516
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(target cells incubated with antibody but without effector cells, and target cells in-
cubatedwith effectors but withoutantibody)had grownto confluence, while no tumor
cell colonies hadgrown from the wells originally containing tumorcells, monocytes,
and antibody. These experiments suggest that the absence of detectable tumor-
associated antigens in our assay is reliable evidence that viable tumor cellshave been
eliminated.
M-CSFSupportsSurvivalandDifferentiation ofMonocytes inMinimalMedium.
￿
Mono-
cytes cultured in human serum underwent the morphologic changes characteristic
of in vitro differentiation(13-15); they became large, spreadinggranular cells. Meta-
bolic activity, as measured by mitochondrial reduction of MTT, increased steadily
over the period ofculture. Monocytescultured in human serumusuallyshowed some
ADCC against tumortargets, but there was substantial variation in ADCC activity
between lots of human serum. The effects of recombinant M-CSF on cultures con-
taining human serumwas difficultto assess given this variability, butwith repeated
experiments apattern ofenhancement by M-CSF, over and abovethe effects of serum
alone, became apparent. To observe the action of M-CSF on monocyte ADCC in
isolationfrom the unpredictable effects ofhumanserum, we used aminimal medium
consisting of 10% heat-inactivated bovine serum in RPMI 1640.
Figure 3 shows that, by itself, this medium did not support metabolic activation
in culture or the development of ADCC ; in fact, most monocytes were dead by day
12 in bovine serum alone. However, when supplemented with 100 U/ml of recom-
binant M-CSF this medium permitted reproducible survival and differentiation of
monocytes. Fig. 3 A compares MTT reduction by monocytes cultured in human
and bovine serum, with or without added M-CSF. The increased metabolic activity
with human serum seen in this experiment was a reproducible feature ofthese cul-
tures, but did not correlatewith ADCC activity. Fig. 3B shows parallel experiments
(using the same effector cells) measuring ADCC againstSKMel-1. The figure shows
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Effects of in vitro culture on metabolic activity and ADCC by human monocytes.
(A) Human peripheral blood monocytes were cultured for 2-10 d in either 20% human serum
or minimal medium, with and without 100 U/ml M-CSF. Replicate cultures were assayed on
days 1, 3, 8, and 10 for metabolic activity by MTT reduction. (Opencircles) Human serum with
M-CSF; (solid circles) humanserumalone; (opensquares)minimalmedium with M-CSF;(solidsquares)
minimalmedium alone. (B)Monocytes were cultured as abovefor10 d, then assayed forcytotox-
icity against SKMe1-1 (E/T = 1:1)as described in MaterialsandMethods. (Openbars)with 3F8
antibody (2 jig/ml); (solid bars)withoutantibody. (1) humanserum alone;(2)human serumwith
M-CSF; (3) minimal serum alone; (4) minimal medium with M-CSF.oneexperiment in whichADCC by monocytes cultured in humanserum was high.
Other experiments showed little or no ADCC with human serum alone. The av-
erage ADCC was 42 t 34% for human serum alone, 86 ± 44% for human with
M-CSF, 19 t 10% forminimalmedium alone, and 93 t 6% forminimal medium
with M-CSF (average of7-10 experiments with the target cell line at an E/T ratio
of 4:1).
There were clear and reproducible morphologic differences between monocytes
cultured in humanserumandthosecultured inminimalmediumplusM-CSR Human
serum produced round, very granular cells. M-CSF produced less granular, more
spindle-shaped cells. When both human serum and M-CSF were present, the mono-
cytes had the morphology associated with human serum.
Monocytes Acquire theAbility to Mediate ADCC During Culture in M-CSF.
￿
Freshmono-
cytes (cultured C2 d) did not mediate significant cytotoxicity with orwithout anti-
body at the E/T ratios used in our assays. Fig. 4 shows the development ofcytotox-
10 d. A target cell line (SKMel-31) sensitive to both ADCC and
ent killing is presented, to show that both antibody dependent
and antibody independent killing emerge at about the same rate, although ADCC
is more efficient. Other celllines tested (SKMel-1, LAN-1) showed similar patterns.
Tomoreaccurately measure cytotoxicity oneach specific day, 24h(rather than 72 h)
incubationswere used for the experiments in Fig. 4. Time-course experiments per-
formed at 12, 24, 48, and 72 h of co-incubation had previously shown that killing
reachedaplateauby 12-24h. Thereafter itappearedthat survivingtumorcellsprolifer-
ated at approximately the same rate as controls, since cytotoxicity (expressed as a
percentage ofcontrol) did not change significantly over the next 48 h. Fig. 5 shows
the responseofmonocytesto culture for9-11 d invariousconcentrations ofM-CSF
Antibody-independent killing varied considerably from donor to donor and from
day to day, but did not exceeded 75% even in the more sensitive cell lines. In con-
trast, ADCC was reproducibly high after culture in 100 U/ml ofM-CSF, and usu-
ally reached 95-100% at E/T ratios of 2:1 or 4:1 by day 10.
Fig. 6 shows cytotoxicity as determined by our assay for each ofthe six different
melanoma andneuroblastomacell lines that we tested. Antibody-independent killing
varied greatlybetweencelllines, but all lines were sensitivetoADCC, andall reached
90-100% cytotoxicity at an E/T ratio of 8:1 or less.
It should benotedthat ourassay measures cytotoxicitybycomparingthenumber
ofsurviving target cellspresent at the end of72 h with the numberofcontrol target
cellspresent after incubation withouteffectors. Therefore, itcannot differentiate be-
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FIGURE 4
￿
Time course for thedevelopment of monocyte cyto-
toxicity during culturein M-CSE Humanperipheral bloodmono-
cyteswere cultured for2-10 din minimalmedium with 100U/ml
M-CSF. Target cells (SKMel-31, E/T = 4:1)were addedon days
2, 4, 6, 8, and 10,andco-incubated for 18 h.Cytotoxicity was mea-
suredby ELISA, as described in MaterialsandMethods. (Circles)
with 3F8antibody (2 ug/ml);(squares)withoutantibody. This figure
shows oneofthreesimilar experiments usingtwodonors andtwo
target cell lines.518
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tween growth inhibition (cytostasis) and target cell killing. During 72 h target cells
underwentat most twodoublings. Thus, cytostasis at most might account fora 75%
reduction in the number of surviving target cells relative to controls. Between 75
and 100%, however, cytostasis alone could not account for the observed reduction
in target cells, and true target cell killing must be present. Our tumor outgrowth
experiments (described above) had shown us that even a few surviving target cells
would rapidly grow to confluence once removed from the influence of effector cells.
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￿
Dose-response relationship between M-
CSF concentration and development of monocyte
ADCC in culture. Human peripheral blood mono-
cytes were cultured for 9-11 d in minimalmedium
plus various concentrations of M-CSF Target cells
(SKMel-1, E/T = 2:1)were addedandco-incubated
for72 h. Cytotoxicity was determined by ELISA as
described in Materials and Methods. (Circles) with
3F8 antibody (2,ug/ml); (squares) without antibody.
Thedata representthe average of four experiments
usingtwodonors. Thebars show standarddeviation.
Monocytes cultured withoutM-CSFwere virtually
alldead by thetime ofthe assay. Wellsthat hadorig-
inally containedmonocyteswithout M-CSFdidnot
support target cell proliferation as well as thosecon-
taining medium alone (typically 15% growth inhi-
bition), and the cytotoxicity figures have been ad-
justed to reflect this.
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ADCC by M-CSF cultured monocytes against various melanoma and neuroblas-
toma target cell lines. Human peripheral bloodmonocytes were cultured for9-12 din minimal
medium with 100 U/ml M-CSF. Targets were added in various concentrations to achieve the
E/Tratios indicated. Parallel groups received either theanti-GD2 antibody 3F8, 2 Kg/ml (circles),
or medium alone (squares). R24 (anti-GD3, 1:500 ascites) wasused for the cell line shown in C.
After72 hthecultures were assayed forresidual tumorcells by ELISA, as described in Materials
and Methods. (A) SKMel-1 (average offour experiments);(B)M-14; (C)SKMel-28 (two experi-
ments); (D) SKMel-31 (24-h incubation, three experiments); (E) LAl-15n; (F) LAN-1.We thus felt that the region approaching 100% cytotoxicity was more interesting
(and clinically relevant)than partial reductions in target cell number, and ourassay
was designed to detect small numbers of residual target cells.
ADCC Is Specificfor Antibody-coated Target Cells and Requires the Fc Region.
￿
Fig. 7
shows thedose-responsecurveforADCC by cultured monocytes at various concen-
trations of 3F8 antibody. A significant increase in cytotoxicity was detectable at 0.1
jug/ml of 3F8, and the curve appears to reach aplateau at 1-3 hg/ml. These concen-
trations are quite similar to those that we have reported for ADCC by fresh and
IL-2-activated lymphocytes (31), and forADCC by granulocytes (32), using thesame
antibody and target cells. The experiments in this figure were performed at an E/T
ratio of 2:1 . ADCC did not occur in the presence of F(ab')2 fragments of 3F8, even
when tested at concentrations up to 10 ug/ml (100 times the concentration at which
ADCC was detectable with intact antibody).
To test whetherADCC by M-CSFcultured monocytesinvolved therelease of cyto-
toxic factors into the surrounding medium, we co-incubated monocytes with two
target cell lines simultaneously. One target expressedprincipally GD3, and the other
expressed principally GD2. In one experiment (Table I), anti-GD3 antibody was
present during the incubation, resulting in 82-90% cytotoxicity for the GD3+ target.
At the end of 72 h, surviving(GD2 +) bystander cells were assayed by ELISA. Cyto-
toxicity to bystander cells was not increased by the presence of target cells under-
going ADCC . In fact, bystander killing was usually less in the presence of target
cells plus antibody; possibly the large number ofADCC target cells served as com-
petitive inhibitors for nonspecific bystander killing. When another GD3- bystander
cell (LAN-1) was used, we likewise observed no increase, rather a decrease, in by-
stander cytotoxicity during ADCC. In parallel experiments (also presented Table
I), the roles of bystander and target cell were reversed by using an anti-GD2 anti-
body for ADCC. Although the baseline level of bystander cell killing was higher
(due to thesensitivity of SKMel-28 to antibody-independent cytotoxicity), there was
no increase in bystander killing during ADCC. The absence of bystander cytotox-
icitysuggests that ADCC is not principally mediated by soluble factors released into
the medium, nor by depletion of growth factors or nutrients.
In separate experiments, when supernatant was removed from ADCC cultures
(monocytes and targets plus antibody) andadded to fresh targets, therewas no inhi-
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Dose-responserelationship between3F8
antibody concentration and ADCC by M-CSF
cultured monocytes. Human peripheral bloodmono-
cyteswere cultured for 9-14 d in minimal medium
with 100 U/ml M-CSF. Target cells (SKMel-1, E/T
= 2:1)were addedandco-incubated for72 h in the
presence of various concentrations of purified 3F8
antibody. Cytotoxicity was measured by ELISA, as
described in Materials and Methods. The figure
showsthemean offourexperimentsusingtwodonors;
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TABLE I
Absence of Bystander Killing During Macrophage ADCC
Percent cytotoxicity
Peripheral blood monocytes were cultured in minimal medium with 100 U/ml
M-CSF for 10 d. One of two target cell lines, SKMel-28 (GD3'GD2-) or
SKMel-31 (GD3 GD2'), was added (E/T ratio 4:1), with or without antitar-
get cell antibody. In some wells, both cell lines were present throughout the
72-h assay . Cytotoxicity was determined by separately measuring residual
GD2' and GD3+ cells in replicate wells by ELISA, as described in Materials
and Methods. The data are from one of three experiements with similar results.
When R24 (anti-GD3, 1 :500 ascites) was present during the assay, SKMel-28
served as the target for ADCC and SKMel-31 was considered the bystander
cell. When 3F8 (anti-GD2, 2 Ag/ml) was present, the roles were reversed.
Some increase in bystander cell killing was observable in the presence ofsup-
posedly "irrelevant" antibody, which we attribute to low-level binding of anti-
body to the bystander cells via specific and nonspecific interactions.
bition of oxidative metabolism as measured by MTT reduction. This suggests that
a soluble factor such as respiratory inhibition factor (33) does not play amajor role
in ADCC by M-CSFcultured monocytes. In preliminary experiments, when mono-
cytes from a patient with chronic granulomatous disease were cultured in M-CSF,
they mediated significant ADCC (92% killing against SKMel-31 at an E/T ratio
of 8:1).
Immunophenotype ofM-CSF-cultured Monocytes.
￿
Monocytes were cultured for 10 d
in M-CSF and assayed for the expression of several monocyte/macrophage surface
antigens (Table II). Nonspecific binding of irrelevant antibodies to cultured mono-
cytes was high (N 10 times that seen with fresh monocytes), and made interpretation
of weakly positive staining difficult. We arbitrarily defined cells with a fluorescence
intensity >98% ofthe "negative" controls as being positive. However, cultured mono-
cytes showed a single peak (not a bimodal distribution) forall the antibodies shown,
suggestive ofa relatively homogeneous population. Thus, the mean fluorescence for
each antibody may be a more useful measurement of antigen expression, and it is
included in Table II to facilitate comparison. Leu19 stained cultured monocytes no
more strongly than didtheirrelevant antibodies, suggesting that contaminatingNK
cells are not present in our cultures . Note that many of the activated monocytes
expressed the CD16 (low-affinity Fc receptor, FcRIII) antigen, which is not found
on fresh monocytes.
Target
cell
Bystander
cell
Antibody*
Anti-GD2 Anti-GD3
Target
cells
Bystander
cells
SKMel-28 - - - 55 -
SKMel-28 - - + 82 -
- SKMel-31 - - - 0
- SKMel-31 - + - 18:
SKMel-28 SKMel-31 - - 61 0
SKMel-28 SKMel-31 - + 90 12
SKMel-31 - - - 0 -
SKMel-31 - + - 93 -
- SKMel-28 - - - 33
- SKMel-28 + - - 451
SKMel-31 SKMel-28 - - 0 30
SKMel-31 SKMel-28 + - 86 39MUNN AND CHEUNG
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TABLE II
Immunophenotype of Monocytes Cultured in M-CSF
Monocytes were cultured for 10 d in minimal medium with 100 U/ml M-CSF,
then harvested with EDTA and stained for analysis by flow cytometry. The
data are from one of two experiments with similar results.
Due to the large amount of nonspecific antibody binding by activated macro-
phages, positive cells were defined as those with a fluorescence intensity >98%
of cells stained with the least reactive of the control antibodies (Leu19).
1 Relative mean fluorescence, measured on an arbitrary 4-decade logarithmic
scale, with the least reactive ofthe control antibodies defined as 1 .0. All mea-
surements were made on the same day at the same flow cytometer settings.
Discussion
We have examined the emergence of antitumorADCC during the differentiation
of monocytes in culture with human serum and recombinant M-CSF. We have es-
tablished that M-CSF is able to supportthe differentiation and activation ofmono-
cytes, even in a minimal medium that alone does not support differentiation. After
culture in M-CSFor human serum, monocytesacquirethe ability to mediateefficient
antitumor ADCC with two IgG3 murine mAb. We have demonstrated efficient
ADCC at E/T ratios as low as 1:1, with 90-100% killing usually reached at an E/T
ratio of4:1 or 8:1 . This is significantly higher cytotoxicity than is generallyreported
in the literature for monocytes or macrophages.
To detect survivingtarget cells aftermonocyte ADCC, amodified ELISAmethod
was used, in which surviving tumor cells served as the target antigen. Most tumor
cell lines did not remain adherent during the wash steps of our ELISA, so to im-
mobilize them we relied on fixation with glutaraldehyde. This was effective, but re-
stricted our choice of antigens to those which survived fixation. Also, due to the
high nonspecific binding of most murine antibody subclasses to activated macro-
phages, we found that only IgG3 antibodies worked satisfactorily in the ELISA. We
used antibodies against two glycolipid antigens, GD2 and GD3, which are strongly
expressedon variousmelanoma andneuroblastorna cell lines, andwhichare unaffected
by glutaraldehyde. For cell lines that didnot expressboth antigens, we used the same
antibody for ADCC and ELISA (first confirming by flow cytometry that these an-
tigens did not modulate, even after prolonged exposure to antibody).
To ensure that no population of antigen-negative cells was escaping detection by
ELISA, we used flow cytometry to reveal residual tumor cells. Using two-color im-
munofluorescence and a cocktail of antitumor antibodies, we could reliably detect
>98% of the target cells and distinguish them from the effector cells. After a 72-h
ADCC incubation, <2% residual tumorcells were detectable by flow cytometry. This
high levelofcytotoxicity suggestedby ELISAandflow cytometrywas furtherconfirmed
by the absence of proliferating tumor cells after ADCC.
Antibody Antigen
Percent
positive"
Relative mean
fluorescence)
Controls 2 1 .0-1.6
Leu19 2 1 .0
3G8 CD16 53 2.89
OKM-1 CDllb (CR3) 82 5.48
L243 la 76 7.67
MY4 CD14 59 3.69522
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It is noteworthy that two widely used indicators of target cell death, release of
"Cr and release of [3H]TdR, underestimated cytotoxicity significantly when com-
pared with either visual inspection or immunologic detection of surviving tumor
cells. The disparitywas especially marked in the case ofchromium release (0% specific
lysis, vs. 100% cytotoxicity by ELISA), but thymidine release also consistently un-
derestimated cytotoxicity. A similar phenomenon hasbeen reported previously with
thekillingof mastocytoma target cells by endotoxin-activated rat liver macrophages
(24). In that study, Gardner et al. observed no release of 5'C r after macrophage cy-
totoxicity, and only partial release of [3H]TdR (with a flat dose-response curve to
increasing E/T ratio very similar to our Fig. 1 B). They were able to show by elec-
tron microscopy that target cellswere beingphagocytized intact by activated macro-
phages, and that the chromium from the target cells remained within the macro-
phages after phagocytosis. The similarity oftheirdata to ours suggests that phagocytosis
maybe one reason that radionuclide release assays appear to underestimate cytotox-
icity by monocyte/macrophages for certain cell lines.
We did not observe killing of bystander cells during ADCC by cultured mono-
cytes. Further, supernatant from ADCC cultures had no detectable effect on the
ability of target cells to reduce MTT to formazan (a measureof metabolicactivity).
These observations suggest that soluble mediators released into the surrounding
medium didnot play a principal role in target cell killing. This is in agreement with
published studies on ADCC by rat macrophages (34). However, it has also been
reported that tumor necrosis factor may not need to be secreted in order to cause
tumor cell death (35). It was interesting to us that our one donor with chronic
granulomatous disease also showed efficient ADCC . Further experiments to eluci-
date the role of soluble factors and oxidative intermediates in ADCC by M-CSF
cultured monocytes are in progress.
We found that most M-CSFcultured monocytes expressed the low-affinity Fc
receptor (FcRIII, CD16), and mediated ADCC with murine IgG3 antibodies.
FcRIII is not normally present on fresh human monocytes, but it is expressed on
peritoneal and alveolar macrophages (36) and is acquired by monocytes after 7-9 of
culture in vitro (37). It is the receptor used by lmphocytes and granulocytes forADCC
(38), and it has a high affinity for murine IgG3 antibodies (39). Further experiments
are in progress to elucidate the role of FcRIII in ADCC by cultured monocytes.
It is unclear whether monocytes cultured in vitroin human serum or M-CSF un-
dergo true activation, or whetherthey merely follow apath ofdifferentiation similar
to that which they would follow in vivo. The ability of both serum and M-CSF to
induce antitumor ADCC may reflect a common pathway of activation, possibly
through M-CSF present in the human serum used, or secreted by the monocytes
themselves. Rodents have detectable levels of M-CSF activity in serum (40), and
although it has been more difficult to measure M-CSF in human serum, the effects
of human serum and M-CSF in culture appear to be similar (16). The degree to
which cultured monocytes resemble restingor activated tissue macrophages will re-
quire further studies to elucidate.
The ability of M-CSF cultured monocytes to use murine IgG3 antibodies for
efficientADCC in vitro mayhave implications for in vivo immunotherapy. 3F8 and
other antibodies of the IgG3 subclass have been shown to mediate antitumor cyto-
toxicity through activation of complement (41), and through ADCC by granulo-We thank Genetics Institute, Boston, MA for their generous supply of recombinanthuman
M-CSF, Dr. Unkeless for the antibody 3G8, and Dr. Griffin for antimonocyte antibodies.
We also thank Ms. Patricia Halloran for her technical assistance.
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cytes(32), lymphocytes, andIL-2-activated lymphocytes (31). PhaseI-II clinical trials
are under way using 3F8 as a single agent, and have shown antitumor responses
(complete and partialremissions)in patients with progressive and refractory neuro-
blastoma and melanoma (42). The observationthat apparently complete target cell
killing could often be achieved by ADCC at low E/T ratios was interesting to us.
A long-term assay at a low E/T ratios may more realistically reflect the conditions
prevailing in vivo than short-term assays using alarge number ofeffector cells. Cells
of the monocyte/macrophage lineage have been noted to be resident in many pri-
mary tumors and tumor metastases (as abundant as 50% of cells) (43, 44), and we
have seen tumorinfiltration with monocytes, lymphocytes, and mast cellsin patients
receiving 3F8 (unpublished results). The ability to target tumor-cytotoxic mono-
cytes and macrophages using mAb may have therapeutic potential in the im-
munotherapy of malignant diseases.
Summary
Macrophage colony-stimulating factor (M-CSF) is known to stimulate prolifera-
tion of monocyte/macrophage progenitors and enhance in vitro antitumorcytotox-
icity by murine macrophages. In this paperwe have shown that recombinanthuman
M-CSF causes human peripheral blood monocytes to differentiate in culture into
metabolically active macrophage-like cells. These cells mediatevery efficient antibody-
dependent cellular cytotoxicity (ADCC) against human melanoma and neuroblas-
toma cell lines in the presence of two murine IgG3 mAbs (3F8 and R24). They also
mediateantibody-independent cytotoxicity (or cytostasis) to alesser extent. Human
serum had an inconsistent effect on ADCC, but often induced similar high levels
ofADCC. Cytotoxicity wasmeasured usinganovel ELISAto detect surviving tumor
cells after ADCC. Two conventional isotope-release assays ("Cr and [3H]TdR) un-
derestimated or entirely failed to detect ADCC by M-CSFactivated monocytes. Op-
timal activation occurred with 100-300 U/ml of M-CSF, and required 9-11 d for
completion. Most of the M-CSF cultured monocytes expressed the low-affinity Fc
receptor (CD16). ADCC by cells of the monocyte/macrophage lineage using murine
IgG3 mAbs may have significance for the immunotherapy of human malignancies.
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